Laquinimod program cancelled in MS


Teva Pharmaceuticals has announced that it will no longer pursue the commercial development of laquinimod, a small-molecule aryl hydrocarbon receptor activator, in neurodegenerative diseases. The development and commercialization rights will revert back to Active Biotech, the company that originated the molecule.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page